SGO members are eligible for a discounted fee to access this content. Log in to view your correct price.

This session is from the SGO 2025 Annual Meeting on Women's Cancer.

After decades of slow progress, 2024 has been a banner year of new FDA approved indications to treat gynecologic cancers, including regular approval for two new drugs. This session introduces the FDA review process using the 2024 gynecologic cancer approvals as the backdrop and reviews emerging data on the impact of FDA approvals on clinical outcomes.

Moderator Introductions
Stephanie Wethington, MD

Improved 5-year Survival Rates After the Influx of FDA-approved Novel Therapeutics for Recurrent or Metastatic Cervical Cancer
Elizabeth V. Adams, MD

Trends in FDA Approvals of Gynecologic Oncology Therapeutics from 2019-2024
Kaitlyn Dinkins, MD

Regulatory Considerations for Gynecologic Malignancies
Stephanie Wethington, MD
 

This course is not eligible for CE.

This was recorded in March 2025 in Seattle, WA.